250 results about "Tromethamine" patented technology

A pharmaceutical oral formulation for delivering nicotine in any form to a subject by transmucosal uptake in the oral cavity comprising nicotine in any form, wherein said oral formulation is buffered with at least trometamol. Also contemplated is a method for the oral delivery of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as methods for manufacturing the oral formulation, the use of the oral formulation for obtaining transmucosal uptake of nicotine in the oral cavity of a subject, and use of nicotine for the production of an oral formulation for the treatment of a disease selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control.

Disclosed is an ophthalmic composition containing (A) not less than 50,000 units / 100 mL of vitamin A, (B) not less than 0.4 W / V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.

The invention provides sacubitril derivatives and medicine compositions, preparation methods and application thereof and belongs to the fields of medicine compounds and preparation thereof. The sacubitril derivatives comprise sacubitril lithium salt, sacubitril kali salt, sacubitril magnesium salt, sacubitril calcium salt, sacubitril strontium salt, sacubitril zinc salt, sacubitril ferric salt, sacubitril ammonium salt, sacubitril diethylamine salt, sacubitril ethylenediamine salt, sacubitril piperazine salt, sacubitril N-(2-ethoxyl)-pyrrolidine salt, sacubitril choline salt, sacubitril cholamine salt, sacubitril diethanol amine salt, sacubitril triethanolamine salt, sacubitril tromethamine salt, sacubitril meglumine salt, sacubitril diisopropylamine salt, sacubitril tert-butylamine salt, sacubitril N, N'-bis-benzyl ethylenediamine salt, sacubitril L-lysine salt, sacubitril L-arginine salt or sacubitril L-histidine salt.

The invention relates to a micromolecular donkey-hide gelatin essence anti-aging facial mask, which contains the following components: glycerin, methylpropanediol, glyceryl polyether-26, 1,2-hexanediol, p-hydroxyacetophenone, butanediol, PEG-60 hydrogenated castor oil, panthenol, xanthan gum, allantoin, carbomer, glycerin polyacrylate, tromethamine, sodium hyaluronate, EDTA disodium, glycerin acrylate / acrylic copolymer, phenoxyethanol, propylene glycol, proplis extract, a PVM / MA copolymer, dipotassium glycyrrhizinate, essence, silk amino acids, beta-glucan, BAMBUSA VULGARIS WATER bambusa vulgaris water, hydrolyzed collagen, rice extract, glycine ussuriensis seed extract, sesame seed extract, chondrus crispus extract, ethylhexylglycerin, polysorbates-20, potassium chloride, locust bean gum,dipotassium phosphate, sodium citrate, hydrolyzed hyaluronic acid, glucose, calcium lactate, glucomannan, sodium acetylated hyaluronate and acetyl hexapeptide-8. The micromolecular donkey-hide gelatin essence anti-aging facial mask has the efficacies of supplementing skin nutrition, moisturizing, removing wrinkles and resisting senility.

The invention relates to lomoxicam freeze-dried powder injection and a preparation method thereof. The freeze-dried powder injection comprises omoxicam, mannite, tromethamine, EDTA and pH regulator. The dosage of the mannite is 3.5 to 8.5 g of mannite per gram of lomoxicam, and the dosage of the EDTA is 0.015 to 0.025g of EDTA per gram of lomoxicam. The invention adopts EDTA to replace EDTA-disodium salt and selects the dosages of the mannite and EDTA so that the clarity of the reconstituted obtained freeze-dried powder is greatly improved, and the formability is good; in addition, the invention adopts two pH regulators, in the process, one pH regulator is used to regulate the solution to a pH range, then the other pH regulator is used to regulate the solution to another pH range, and the freeze drying technology is controlled strictly. The prepared freeze-dried powder injection has great improvement of stability and favorable resolubity.

Efforts to extend myocardial preservation for transplantation by perfusion with prior crystalloid based solutions have been limited by edema and compromised function. Hypothermic perfusion preservation with a polyethylene glycol (PEG) conjugated hemoglobin solution extends preservation times. The polyethylene glycol (PEG) conjugated hemoglobin solution comprises PEG-Hb, and at least one of the constituents selected from the group of human albumin, dextrose, heparin sodium, lidocaine HCl, MgSO4, KCl, CaCl2, Tromethamine (THAM) solution, NaCl, NaHCO3, and Na2HPO4 / NaH2PO4. Comparison of cardiac function after continuous perfusion using a hypocalcemic normokalemic crystalloid perfusate is made with and without the addition of PEG-Hemoglobin (Hb).

The invention provides a process for synthesizing pulveres fosfomycin trometamol by using phosphonomycin sodium or neutral phosphonomycin sodium containing small amount of organic acid as raw material through the steps of, subjecting 10-16 times of type H cationic ion-exchange resin to exchange reaction in methanol solution at low-temperature, with the methanol solution acting as eluent, thus preparing the methanol solution containing fosfomycin acid, neutralizing the methanol solution with right amount of tromethamine or fosfomycin methanol tromethamine salt so as to obtain the methanol solution of pulveres fosfomycin trometamol, and the end product of the methanol solution of pulveres fosfomycin trometamol is obtained from the methanol solution of pulveres fosfomycin trometamol from decolorizing, filtering, condensing, extracting, filtering and drying.

The invention belongs to the technical field of medicine, in particular to a drug composition of gargle which contains sodium dichlorophenolate and can relieve pain and be anti-inflammatory for the oral inflammation disease; wherein the drug composition comprises the following components by percentage: 0.10 to 30 percent of sodium dichlorophenolate hydroxypropyl-Beta-cyclodextrin inclusion (equal to 0.065 to 0.20 percent of concentration of sodium dichlorophenolate), 0.01 to 0.10 percent of lidocaine hydrochloride, 0.10 to 5.0 percent of borax, 0.1 to 2.0 percent of boric acid, 0.1 to 10 percent of glycerin, 0.10 to 5.0 percent of sodium bicarbonate, 0.001 to 0.10 percent of vitamin B12, 0.02 to 1.0 percent of tromethamine, 0.01 to 5.0 percent of sucralose, 0.10 to 5.0 percent of peppermint essence and 0.01 to 1.0 percent of sodium benzoate; a proper amount of pharmaceutical caramel color and water for injection is added till to reach the needed weight / volume concentration. All the above components are weighted by weight / volume percentage; the aqueous solution of the composition has the pH value of 6.5 to 9.0. The composition has little thrill to oral mucosa, stable storage for long time and good biological tolerance and has fast and long-lasting curative effect for relieving pain and being anti-inflammatory to the oral inflammation disease.

The invention discloses a preparation method of R-lipoic acid tromethamine salt and belongs to the field of organic medicinal chemistry. The method includes the steps that (S)-6,8-dichloro ethyl caprylate and sulphur are put into a reaction vessel, the temperature is raised, a cyclization reaction is carried out, the temperature is preserved, extraction is carried out with a first organic solvent, concentration is carried out, and cyclization liquid is obtained; then, a hydrolysis reaction is carried out, cooling is carried out, and hydrolysis liquid is obtained; a second organic solvent is added into the hydrolysis liquid, the pH value is regulated, extraction is carried out, an obtained organic layer is washed with water to be neutral, the second organic solvent is removed at reduced pressure, and an initial product is obtained; mixed liquor is added into the initial product, the temperature is raised, a first filter aid is added, stirring adsorption is carried out, filtration is carried out, and light yellow liquid is obtained; cooling is carried out to separate out crystals, and R-lipoic acid is obtained; R-lipoic acid is dissolved, trihydroxymethyl aminomethane is added, the temperature is raised for solution, a second filter aid is added for filtration, and light yellow liquid is obtained; cooling is carried out to separate out crystals, centrifugal drying is carried out, and the finished product is obtained. According to the method, few steps are needed, efficiency is high, energy is saved, and waste discharge is reduced.

The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amounts of N-(2-yrazine) carbonyl-L-phenylalanine-L-leucine boronic acid or its salts or its derivatives and tromethamine wherein the composition is stable.

The invention provides a method for reducing esophageal irritation associated with alpha-lipoic acid upon oral administration through the use of the trometamol salt of alpha-lipoic acid. The present invention also provides for the increased solubility of alpha-lipoic acid through the use of the trometamol salt of alpha-lipoic acid. The trometamol salt of alpha-lipoic acid, as provided by the present invention can be used as a substitute for regular, non-salt forms alpha-lipoic acid in dietary supplement compositions.

The present invention relates to a non-steroidal anti-inflammatory drug of ketorolac tromethamine salt, which has the functions of strong acesodyne, moderate anti-inflammation and antipyresis. The present invention applies a synthesis route preparing the compound ketorolac tromethamine salt, the technique applies an one-pot method, the reaction process from 2-benzoyl pyrrole to the ketorolac tromethamine salt can be continuously carried out, extraction and purification are not needed, materials can be easily obtained, labor intensity is reduced, the operational environment is improved, the cost of industrialized production is greatly reduced, environmental pollution is reduced, the loss of materials and products is reduced, and the yield rate is increased.

The invention discloses a preparation method of fosfomycin amine salt, which comprises the following steps of: in organic solvent, enabling fosfomycin phenylethylamine salt to react with isocyanate, isothiocyanate, ketene, dipolymer of isocyanate, dipolymer of isothiocyanate or dipolymer of ketene, and tromethamine; or in the organic solvent, enabling fosfomycin bistromethamine to react with isocyanate, isothiocyanate, ketene, dipolymer of isocyanate, dipolymer of isothiocyanate or dipolymer of ketene. The preparation method provided by the invention has the advantages that the fosfomycin amine salt can be prepared in one step only, a low-temperature ion exchange column is not required, the yield is high, the cost is low, the waste gas, waste water and waste residue are less, the reaction conditions are moderate, the energy consumption is low, the operation is convenient to conduct and the method is suitable for industrial production.

The invention discloses a prescription of a ketorolac tromethamine injection and a preparation method. The injection provided by the invention can not only effectively solve the problem that the existing ketorolac tromethamine injection containing ethanol causes irritation while being injected and improve the safety of the drugs and the compliance of the drugs, but also completely avoid the white points caused by the traditional technology after sterilization treatment, and thus the ketorolac tromethamine injection is good in stability, high in safety, reliable in quality and significant in efficacy.

The invention provides a synthesis method for 1,2,4-tromethamine, comprising the following steps: the mixed solution of butene diol, tungsten acid and N-methyl morpholine, and epoxidizing agent are mixed through a mixer which is provided with two channel nozzles and arranged at the top part of a reactor, and then enter the reactor for reaction; the material in the reactor is sent to a nozzle at the top part of the reactor through a circulating pump for recycling use to collect epoxide; the epoxidizing agent is selected from oxygen-rich gases; in the presence of catalysts, the epoxide and ethanol go through hydrogenation reaction, then the 1,2,4-tromethamine is collected. The invention adopts oxygen-rich gas as epoxidizing agent and avoids the introduction of unnecessary media in the reaction system through the pre-mixing in a mixer provided with two channel nozzles; besides, the method of the invention has easily-controlled reaction temperature, less equipment investment and mild operating conditions, which does not use the traditional mercury catalyst and has no pollution to the environment; the reaction yield of the method can reach more than 95%, so the method is easy in industrialized implementation.

The invention discloses an ibuprofen medicinal composition for injection. By adding tromethamine into solution of ibuprofen and arginine, the stability of the ibuprofen medicinal composition in clinical application is improved. Experiments prove that: after being diluted by the sodium chloride injection or glucose injection or sodium lactate Ringers injection, the composition solution can be stably stored for at least 12 hours.

The invention discloses a pemetrexed salt and a preparation method and use thereof, the pemetrexed salt can be dipotassium salt, arginine salt, heme-L-lysinate salt and tromethamine salt of the pemetrexed, and the pemetrexed salt can be used for treatment of various cancers such as mesothelioma, lung cancer and the like.

The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R<1> is halo or cyano; R<2> is C1-C4 alkyl; and R<3> is quinolyl or phenyl substituted with methane sulfonyl; can be synthesised by a novel method and are substantially more soluble than the parent free acids in a range of solvents.

The invention discloses an injection octreotide acetate lyophilized composition and a preparation method thereof. The lyophilized composition comprises octreotide acetate, tromethamine and maleic acid. The preparation method comprises the following steps: weighing octreotide acetate and tromethamine, adding into injection water which is cooled to 10-20 DEG C, and stirring to dissolve; regulating the pH of the liquid medicine to be 4.0-5.0 with maleic acid, filtering, filling and lyophilizing. Compared with the prior art, the lyophilized composition is stable in quality, few in auxiliary varieties and simple in preparation process.

The reagent kit for enzyme detection of blood ammonia consists of tromethamine in 50-150 mmol, Tween-20 in 0.1-2 ml, sodium azide om 0.5-2 g, lactose in 5-50 g, glutamate dehydrogenase in 500-1500 u, alpha-ketoglutaric acid in 2-20 mmol, sodium acetonate in 1-10 mmol, and reducing nicotin-amide-adenine dinuclectide phosphate in 0.1-0.5 mmol. After regulating pH to optimal value of 8.0, the components are dissolved, packed and freeze dried and may be cold stored for two years. After being re-dissolved, the components are stabilized at room temperature for 1 week and cold stored to stabilize for 1 month. The reagent kit has powerful interference resistance, medium hemolysis and chylemia, blood sugar below 20 mmol / L, bilirubin below 0.1 mmol / L, enzyme activity loss less than 5 %, MADPH loss less than 10 %, linearity reaching 0.2 mmol / L, CV inside batch of 3.8 % and CV between batches of 5.1 %, and recovering rate of 96.1 %.

The invention discloses a moisture-retaining body cream. The moisture-retaining body cream employs tromethamine to adjust the acid-base property of a body, utilizes glycolic acid to exert exfoliating and whitening effect on the skin, has good moisture-retaining and moisture-supplementing effect due to usage of hyaluronic acid and arginine, exerts good calming and astringing effect on the skin in virtue of sesame flower extract and has good soothing and anti-inflammation effect on the effect as sensitive plant extract and cactus flower extract are used. The moisture-retaining body cream is especially applicable to skin moistening in autumn and winter.

The invention provides an ozagrel salt which is stable, has functions of inhibiting platelet aggregation and removing blood-vessel convulsion, has good water solubility, and is prepared into a compound suitable for clinical application. The new compound is ozagrel tromethamine; and the ozagrel and the tromethamine are prepared by reaction in a solvent. The compound has good water solubility, strong and long-term stability, and the functions of inhibiting platelet aggregation and removing blood-vessel convulsion.

Pharmaceutical composition of ibuprofen for injection that comprises an aqueous solution of ibuprofen and trometamol. These compositions display a minimal loss of active principle and acceptable increase of impurities after autoclaving, properties that have been demonstrated in various types of containers, such as containers made of plastics such as polypropylene, PVC and polyethylene, as well as in glass containers. These compositions, after undergoing autoclaving, still comply with all the relevant technical specifications of the European Pharmacopoeia and of the USP.

The invention discloses a sub-muscular essence and a preparation method thereof, belongs to the technical field of skin care products, and solves the problem an anti-aging function cannot be effectively achieved in the prior art. The sub-muscular essence is prepared from a group A, a group B, a group C, a group D and the balance water, the group A comprises, in weight percent, 1-4% of glycerin polyether-26, 1-4% of 1, 3-propylene glycol, 1-4% of moisturizing agents A, 1-4% of moisturizing agents B, 1-4% of conditioners A, 1-4% of solvents A, 0.4-2% of 1, 2-hexylene glycol, 0.4-1% of p-hydroxyacetophenone, 0.05-0.5% of ammonium acrylate dimethyl taurine / VP copolymers, 0.03-0.5% of xanthan gum and 0.05-0.15% of EDTA (ethylenediamine tetraacetic acid) disodium salt, the group B comprises, inweight percent, 1-6% of butylene glycol and 0.05-0.4% of carbomer, the group B comprises, in weight percent, 0.05-0.4% of tromethamine, and a group D comprises active substances. According to the sub-muscular essence, excitation of self-activating repair is matched with enhancement of skin barriers, so that overall anti-aging effects are achieved.

The invention discloses application of tromethamine in drugs for treating hyperuricemia and related disease. The tromethamine can serve as a drug in application of treating hyperuricemia, urinary system uric acid calculi and gout, an adult takes 1-7 g of the dose every day, and the medication method is intravenous drip. The tromethamine is used for promoting uric acid to dissolve and discharge, no inorganic ions exist because the tromethamine is organic amine alkali, the inhibiting effect of the inorganic ions can be avoided or weakened, the effect of the tromethamine for promoting uric acid to dissolve and discharge is better than that of sodium bicarbonate, and the tromethamine can be used for treating hyperuricemia, urinary system uric acid calculi and gout. Besides, the tromethamine is a foreign substance, an organic body cannot produce the tromethamine substance, and accordingly, the concentration of the tromethamine in the body is better to control compared with the sodium bicarbonate in the medication process.

The invention relates to a swine fibrin glue powder inhalation and a preparation method and application thereof. The swine fibrin glue powder inhalation comprises swine fibrin original gum lyophilized powder, swine thrombin lyophilized powder, sodium chloride and / or sodium acetate, calcium chloride and / or tromethamine and a physiologically acceptable antistatic agent. The preparation method comprises the following steps of: grinding the components into powder with suitable particle size, then uniformly mixing the powder and filling the mixture. The product is stable and convenient to carry and store and can be directly used without preparation. The swine fibrin glue preparation is sprayed on a wound surface in a powder shape, saves time for operation and wound packing, brings great convenience, has a simple production process and is safe and environmentally-friendly.

This invention discloses trometamol salts of cillin compounds, or their hydrates that can be used to treat bacillosis. As hown in formula 1, the salts comprise trometamol salts of azlocillin, amoxicillin, ampicillin, oxazacillin, furbucillin, cloxacillin, mezlocillin, mecillinam, piperacillin, ticarcillin, floxacillin, hetacillin, cloxacillin and penicillin. This invention provides drug compositions with the salts shown in formula 1 as the active components, and their application in drugs for treating bacillosis.

Provided is a synthetic method of water-solubility biocompatibility monodisperse spherical gold nanometer crystals. The synthetic method of the water-solubility biocompatibility monodisperse spherical gold nanometer crystals comprises the following steps (1) using ultra-pure water to prepare a sodium citrate solution, a chloroauric acid solution, a silver nitrate solution and a glutathione solution or a tromethamine solution; (2) mixing the ultra-pure water, the sodium citrate solution, the chloroauric acid solution and the silver nitrate solution together to form a premixed solution, adding the glutathione solution or the tromethamine solution into the premixed solution to form a mixed solution; when the silver nitrate solution and the ultra-pure water are not used, solutions does not need to be mixed; (3) rapidly injecting the mixed solution into the boiling ultra-pure water which is used in a reaction, or directly injecting the solutions into the boiling ultra-pure water which is used in the reaction; and (4) carrying out heating reflux on the mixture, and naturally cooling extraction to room temperature. The synthetic method of the water-solubility biocompatibility monodisperse spherical gold nanometer crystals has the advantages of being simple in operation, good in repeatability, capable of obtaining the water-solubility biocompatibility monodisperse spherical gold nanometer crystals which are high in quality and can not be obtained in other existing methods.

The invention relates to a new method for synthesizing fosfomycin trometamol, which comprises the following steps: directly oxidizing under the catalysis of a chiral ligand through maleic phosphoric acid, obtaining optically-pure free fosfomycin acid and adding an equivalent of tromethamine for neutral reaction to obtain fosfomycin trometamol.